ArticleACS nano2026
Nongenetic
Article in ACS nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromodulation is central to both fundamental neuroscience and the development of next-generation brain-computer interfaces (BCIs). However, most cell-type-specific neuromodulation strategies rely on genetic approaches such as optogenetics, which, despite their high spatiotemporal precision, can perturb intrinsic neuronal properties and raise concerns regarding off-target effects and gene-expression efficiency, thereby limiting clinical translation. Moreover, achieving true bimodal neuromodulation remains challenging, as single-gene expression typically enables either inhibition or excitation, restricting applications to one-way perturbations rather than bimodal control of neural activity. Here, we establish a nongenetic bimodal neuromodulation platform by integrating cholesterol-functionalized gold nanorods (GNR-CLS) with a multifunctional fiber-based neural (MFN) probe for localized photothermal stimulation and validate its functionality in the mouse brain. The MFN probe combines microfluidic delivery, near-infrared (NIR) light transmission, and electrophysiological recording within a single flexible fiber, enabling submillimeter colocalization of nanoparticles and optical stimuli with electrophysiological verification of photothermal neuromodulation. Using this platform, we demonstrate
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.